BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Indevus Jumps, Endo Slumps on Plans for $637M Merger
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Indevus Jumps, Endo Slumps on Plans for $637M Merger
Jan. 7, 2009
By
Donna Young
No Comments
Shares of Indevus Pharmaceuticals Inc. soared 73.6 percent Tuesday after the Lexington, Mass.-based company said it was being acquired by Endo Pharmaceuticals Holdings Inc. for $4.50 per share, or about $370 million in cash. (BioWorld Today)
BioWorld